摘要
目的探讨非小细胞肺癌(NSCLC)术前诱导化疗后肿块体积变化规律及影响化疗1周期后体积变化规律的相关因素。方法回顾性分析2012年1月～2012年10月齐齐哈尔医学院附属第三医院肿瘤科收住的行多周期诱导化疗的首诊NSCLC患者共60例;通过螺旋CT获取肿瘤图像并采用治疗计划系统(TPS)自带体积测量软件测量肿瘤体积,分析诱导化疗后肿块体积变化规律及影响化疗1周期后体积变化规律的相关因素。结果 NSCLC患者化疗1周期后平均原发灶肿瘤体积较化疗前明显下降,由89.32 cm3降至58.36 cm3,P=0.012<0.05,差异具有显著性;化疗2、3、4周期后肿瘤体积无明显变化,第5周期肿瘤体积出现增大,与第4周期相比P=0.046<0.05,差异具有显著性;第6周期肿瘤体积较第5周期无明显变化。T分期和原始肿瘤体积大小是影响化疗第1周期后肿瘤体积变化的独立影响因素。原始体积≥125 cm3或分期T1-2者化疗1周期后肿块缩小更明显。结论关于非小细胞肺癌术前诱导化疗,1周期后疗效可能达到最佳,连续化疗最好不要超过4周期;肿瘤体积≥125 cm3者或T1-2分期者对诱导化疗更敏感。
To investigate the regular pattern variation of tumor size after chemotherapy,and analyze the possible factors which influence the change of tumor size after chemotherapy.【Methods】60 non-small-cell lung cancer patients with multi-cycle induction chemotherapy which were firstly diagnosed from January 2012 until December 2012 were enrolled in this study.To utilize size measurement software of TPS to measure tumor size,and to retrospective analyze the change of tumor size after each chemotherapy cycle.【Results】The absolute tumor size are different between re-chemotherapy and post-chemotherapy of first cycle,from 89.32 cm3 decrease to 58.36 cm3（P =0.0120.05）,fourth cycle and after fifth cycle（P =0.0460.05）,but the differences between other consecutive cycles have not statistical significance.T staging and the original tumor size are independent prognostic factors of tumor relative size changes after the first cycle chemotherapy.The absolute size of original tumor size125 cm3 group and T1-2 group decrease more.【Conclusions】The best curative effect induction chemotherapy on non-small-cell lung carcinoma is after the first cycle chemotherapy.the most cycles should be no more than four cycles;absolute size of original tumor size125 cm3 group and T1-2 group are more sensitive to induction chemotherapy than other group.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2013年第18期74-77,共4页
China Journal of Modern Medicine
关键词
非小细胞肺癌
肿瘤体积
诱导化疗
non-small-cell lung cancer
tumor size
induction chemotherapy
